Latest Content

Both the reactive and proactive ibrutinib dose-adjustment cohorts of the phase 2 TAILOR study met the primary ORR end point in previously untreated CLL.

Afami-cel received full FDA approval for unresectable or metastatic synovial sarcoma after prior chemotherapy.

PFS was improved only numerically with the use of maintenance dostarlimab vs observation after chemoradiation in high-risk locally advanced cervical cancer.

Eleven Western New York organizations received funding to advance cancer prevention and early detection.

China’s NMPA has satri-cel for pretreated, CLDN18.2-positive, HER2-negative advanced gastric/GEJ adenocarcinoma.

The STELLAR-303 trial met its OS end point with the zanzalintinib regimen in the ITT population but failed to show the same benefit in the NLM subgroup.

Callisia N. Clarke, MD, MS, FACS, FSSO, discusses how earlier alignment between surgeons and medical oncologists on systemic therapy use allows more patients to undergo resection.

The top 5 OncLive TV videos of the week cover insights in renal cell carcinoma, HER2+ breast cancer, multiple myeloma, and chronic lymphocytic leukemia.

Public libraries will play a role in attaining essential reading skills, improving financial literacy, and achieving a degree of critical thinking.

The FDA accepted for review a sBLA for subcutaneous mosunetuzumab plus polatuzumab vedotin in LBCL, a BLA for ozekibart in chondrosarcoma, and more.

Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.

Yale Cancer Center has appointed Ian E. Krop, MD, PhD, as Section Chief of Medical Oncology and Hematology and Deputy Director for Clinical Affairs.

Neoadjuvant nivolumab yielded a 68.2% clinical complete response rate in patients with resectable mismatch repair–deficient endometrial cancer.